23andMe Holding Co.(NASDAQ : ME)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.32%||10.52||0.7%||$735.39m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.60%||201.58||1.9%||$414.73m|
|GILD||Gilead Sciences, Inc.||-2.21%||68.29||1.0%||$401.30m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.46%||574.61||2.7%||$353.89m|
|NTLA||Intellia Therapeutics, Inc.||3.53%||141.85||2.3%||$263.90m|
|CRSP||CRISPR Therapeutics AG||1.70%||121.02||0.6%||$144.72m|
|EXAS||EXACT Sciences Corp.||-3.64%||107.84||18.1%||$123.59m|
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to consumer genetic testing through its Personal Genome Service, and also food and drug administration authorizations for genetic health risk reports. The firmâ€™s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.